Retatrutide GLP-3R (10mg)

Tri-agonist innovation — engineered for next-generation peptide research.

• Retatrutide is a synthetic peptide analog designed as a triple receptor agonist acting on GLP-1, GIP, and glucagon receptors.
• Studied in controlled laboratory research for its potential influence on energy expenditure, glucose regulation, and metabolic pathways.
• Each batch independently verified by Vanguard Laboratory for purity and composition.

Retatrutide (LY3437943) is a long-acting peptide analog that functions as a triple receptor agonist on GLP-1, GIP, and glucagon receptors.

Preclinical studies demonstrate its ability to promote glucose-dependent insulin secretion, increase energy expenditure, and reduce adiposity in animal models

Phase 2 clinical research has further characterized its pharmacodynamic effects on multi-receptor signaling and metabolic outcomes

Regulatory Status: Retatrutide is not FDA-approved for human or veterinary use. It is supplied exclusively for laboratory research applications.